Literature DB >> 21602831

Prostate-specific antigen (PSA) screening: has the pendulum swung too far?

Jason M Phillips1, E David Crawford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21602831      PMCID： PMC3739584          DOI： 10.1038/aja.2011.49

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  10 in total

1.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Authors:  Jonas Hugosson; Sigrid Carlsson; Gunnar Aus; Svante Bergdahl; Ali Khatami; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Erik Holmberg; Hans Lilja
Journal:  Lancet Oncol       Date:  2010-07-02       Impact factor: 41.316

2.  Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.

Authors:  Michael W Drazer; Dezheng Huo; Mara A Schonberg; Aria Razmaria; Scott E Eggener
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

Review 3.  The role of anxiety in prostate carcinoma: a structured review of the literature.

Authors:  William Dale; Pinar Bilir; Misop Han; David Meltzer
Journal:  Cancer       Date:  2005-08-01       Impact factor: 6.860

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  PSA screening among elderly men with limited life expectancies.

Authors:  Louise C Walter; Daniel Bertenthal; Karla Lindquist; Badrinath R Konety
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

6.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.

Authors:  W J Catalona; D S Smith; T L Ratliff; K M Dodds; D E Coplen; J J Yuan; J A Petros; G L Andriole
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

7.  Prostate specific antigen best practice statement: 2009 update.

Authors:  Kirsten L Greene; Peter C Albertsen; Richard J Babaian; H Ballentine Carter; Peter H Gann; Misop Han; Deborah Ann Kuban; A Oliver Sartor; Janet L Stanford; Anthony Zietman; Peter Carroll
Journal:  J Urol       Date:  2009-09-24       Impact factor: 7.450

8.  Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.

Authors:  Patricia R Slev; Sonia L La'ulu; William L Roberts
Journal:  Am J Clin Pathol       Date:  2008-06       Impact factor: 2.493

9.  Screening for prostate cancer. A decision analytic view.

Authors:  M D Krahn; J E Mahoney; M H Eckman; J Trachtenberg; S G Pauker; A S Detsky
Journal:  JAMA       Date:  1994-09-14       Impact factor: 56.272

10.  Standardization of PSA measures: a reappraisal and an experience with WHO calibration of Beckman Coulter Access Hybritech total and free PSA.

Authors:  G Vignati; L Giovanelli
Journal:  Int J Biol Markers       Date:  2007 Oct-Dec       Impact factor: 3.248
  10 in total
  3 in total

1.  Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer.

Authors:  Hui-Jie Jia; Yang Li; Jin-Guo Wang; Ling Zhang; Hai-Tao Zhang; Xue-Jian Zhao; Masaaki Kuwahara
Journal:  Asian J Androl       Date:  2013-01-21       Impact factor: 3.285

2.  External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort.

Authors:  Yao Zhu; Jin-You Wang; Yi-Jun Shen; Bo Dai; Chun-Guang Ma; Wen-Jun Xiao; Guo-Wen Lin; Xu-Dong Yao; Shi-Lin Zhang; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2012-05-07       Impact factor: 3.285

Review 3.  Prostate-specific antigen: any successor in sight?

Authors:  Aniebietabasi S Obort; Mary B Ajadi; Oluyemi Akinloye
Journal:  Rev Urol       Date:  2013
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.